Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Immunotherapy Esophagus Cancer × nedaplatin × Gastrointestinal × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Neoplasms 9 Esophageal Squamous Cell Carcinoma 8 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Recurrence 1 Ovarian Neoplasms 1 Immunotherapy Esophagus Cancer 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

tislelizumab 1 nedaplatin 1 Radiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05515315 2024-02-07

Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

Fuzhou General Hospital

Phase 2 Recruiting

Gastrointestinal

Immunotherapy Esophagus Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡